Previous Close | 9.56 |
Open | 9.57 |
Bid | 9.26 x 100 |
Ask | 9.31 x 200 |
Day's Range | 9.20 - 9.68 |
52 Week Range | 6.06 - 14.34 |
Volume | |
Avg. Volume | 1,006,529 |
Market Cap | 505.539M |
Beta (5Y Monthly) | 0.96 |
PE Ratio (TTM) | 3.13 |
EPS (TTM) | 2.97 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 17.78 |
Subscribe to Yahoo Finance Plus to view Fair Value for VYGR
LEXINGTON, Mass., March 26, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, has entered into an employment agreement with Toby Ferguson, M.D., Ph.D. that, among other things, provides for the grant to Dr. Ferguson of a non-qualified stock option and restricted stock units as an inducement material to Dr. Ferguson’s entering into employment with Voyager. The inducement awards were approved by the Compensati
LEXINGTON, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced the appointment of Toby Ferguson, M.D., Ph.D., as Chief Medical Officer (CMO), effective March 25, 2024. Ferguson is a skilled and experienced healthcare executive with a proven record in advancing portfolios of novel therapies across diverse indications in central nervous system (CNS), neuromuscular, and rare disea
In this article, we discuss 12 most undervalued biotech stocks to buy according to hedge funds. If you want to skip our discussion on the biotech industry, head over to 5 Most Undervalued Biotech Stocks To Buy According To Hedge Funds. Fitch Ratings maintains a Neutral outlook for the global pharmaceutical and biotech industry in […]